Astellas Pharma Korea, Inc.
Clinical trials sponsored by Astellas Pharma Korea, Inc., explained in plain language.
Korean subsidiary of Astellas Pharma, a global pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- South korea tracks Real-World safety of bladder cancer drug PADCEV Results expected Jul 2027 (estimated)
-
New study tracks safety of VYLOY in everyday cancer care
Disease control Recruiting nowThis study monitors 377 South Korean patients with advanced stomach or gastroesophageal junction cancer who receive VYLOY (zolbetuximab) as part of their normal treatment. Researchers will track side effects and how long the cancer stays stable. The goal is to confirm the drug's …
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
South korea tracks Real-World safety of bladder cancer drug PADCEV
Knowledge-focused Recruiting nowThis study monitors 202 adults in South Korea with advanced bladder cancer who are receiving the drug PADCEV (enfortumab vedotin) as part of their normal care. Researchers will track side effects and how well the cancer responds for up to a year. No new treatment is given; the go…
Sponsor: Astellas Pharma Korea, Inc. • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC